



(51) International Patent Classification:

G01N 33/68 (2006.01) C07K 14/775 (2006.01)
A61K 38/17 (2006.01) G01N 33/92 (2006.01)
A61K 39/00 (2006.01)

(21) International Application Number:

PCT/IB2024/000624

(22) International Filing Date:

30 October 2024 (30.10.2024)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

63/594,669 31 October 2023 (31.10.2023) US

(71) Applicant: ABIONYX PHARMA SA [FR/FR]; 33-43 Avenue Georges Pompidou, Batiment D2, 31130 Balma (FR).

(72) Inventors: TUPIN, Cyrille; c/o Abionyx Pharma SA, 33-43 Avenue Georges Pompidou, Batiment D2, 31130 Balma (FR). PEYROTTE, Constance; c/o Abionyx Pharma SA, 33-43 Avenue Georges Pompidou, Batiment D2, 31130 Balma (FR). BARBARAS, Ronald; c/o Abionyx Pharma

SA, 33-43 Avenue Georges Pompidou, Batiment D2, 31130 Balma (FR).

(74) Agent: HOFFMANN EITLE PATENT- UND RECHTSANWÄLTE PARTMBB, ASSOCIATION NO. 151; Arabellastraße 30, 81925 Munich (DE).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, MG, MK, MN, MU, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, CV, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SC, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ,

(54) Title: LIPID BINDING PROTEIN MOLECULE THERAPY




FIG. 1

(57) Abstract: Methods for treating subjects having or at risk of one or more conditions using lipid binding protein molecules. The methods typically comprise measuring a subject's ApoA-1 levels and/or HDL cholesterol levels and administering one or more doses of a lipid binding protein molecule to the subject if the measured ApoA-1 level is below a target ApoA-1 level or a target ApoA-1 range and/or the measured HDL level is below a target HDL level.

[Continued on next page]

DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT,
LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE,
SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN,
GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:

- *with international search report (Art. 21(3))*
- *before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))*
- *with sequence listing part of description (Rule 5.2(a))*